EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:9445 - terazosin
| Formula | C19H25N5O4 |
| Net Charge | 0 |
| Average Mass | 387.440 |
| Monoisotopic Mass | 387.19065 |
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC |
| InChI | InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) |
| InChIKey | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Role: | alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. |
| Applications: | alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. hypoglycemic agent A drug which lowers the blood glucose level. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. antiatherosclerotic agent A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. antiparkinson drug A drug used in the treatment of Parkinson's disease. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| terazosin (CHEBI:9445) has role antiatherosclerotic agent (CHEBI:145947) |
| terazosin (CHEBI:9445) has role antihypertensive agent (CHEBI:35674) |
| terazosin (CHEBI:9445) has role antineoplastic agent (CHEBI:35610) |
| terazosin (CHEBI:9445) has role antiparkinson drug (CHEBI:48407) |
| terazosin (CHEBI:9445) has role cardiovascular drug (CHEBI:35554) |
| terazosin (CHEBI:9445) has role hypoglycemic agent (CHEBI:35526) |
| terazosin (CHEBI:9445) has role α-adrenergic antagonist (CHEBI:37890) |
| terazosin (CHEBI:9445) is a furans (CHEBI:24129) |
| terazosin (CHEBI:9445) is a organic molecular entity (CHEBI:50860) |
| terazosin (CHEBI:9445) is a piperazines (CHEBI:26144) |
| terazosin (CHEBI:9445) is a primary amino compound (CHEBI:50994) |
| terazosin (CHEBI:9445) is a quinazolines (CHEBI:38530) |
| terazosin (CHEBI:9445) is a racemate (CHEBI:60911) |
| Incoming Relation(s) |
| terazosin hydrochloride dihydrate (CHEBI:9446) has part terazosin (CHEBI:9445) |
| IUPAC Name |
|---|
| 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine |
| INNs | Source |
|---|---|
| terazosin | WHO MedNet |
| terazosina | WHO MedNet |
| térazosine | WHO MedNet |
| terazosinum | WHO MedNet |
| Synonyms | Source |
|---|---|
| 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine | ChemIDplus |
| Terazosabb | ChEMBL |
| Terazosin | KEGG COMPOUND |
| Terazosine | KEGG COMPOUND |
| Citations |
|---|